8-K
CONMED Corp (CNMD)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15 (d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
April 30, 2025
CONMED CORPORATION
(Exact name of registrant as specified in its charter)
| Delaware | 001-39218 | 16-0977505 |
|---|---|---|
| (State or other jurisdiction of | (Commission File Number) | (I.R.S. Employer |
| incorporation or organization) | Identification No.) |
11311 Concept Blvd
Largo, Florida 33773
(Address of principal executive offices, including zip code)
(727) 392-6464
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions (See General Instruction A.2 below):
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| --- | --- |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| --- | --- |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| --- | --- |
Securities registered pursuant to Rule 12(b) of the Act
| Title of each class | Trading Symbol(s) | Name of<br> each exchange on which registered |
|---|---|---|
| Common Stock, $0.01 par value | CNMD | NYSE |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 2.02 | Results of Operations and Financial Condition. |
|---|
On April 30, 2025, CONMED Corporation issued a press release announcing financial results for the first quarter ended March 31, 2025. A copy of this press release is attached hereto as Exhibit 99.1.
The information in this Current Report on Form 8-K that is furnished under “Item 2.02. Results of Operations and Financial Condition” and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Act of 1934, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.
| Item 9.01 | Financial Statements and Exhibits. |
|---|
| (d) | Exhibits |
|---|
The following exhibits are included herewith:
| Exhibit No. | Description of Exhibit |
|---|---|
| 99.1 | Press Release dated April 30, 2025, issued by CONMED Corporation. |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: April 30, 2025 | CONMED CORPORATION | |
|---|---|---|
| (Registrant) | ||
| By: | /s/ Todd W. Garner | |
| Name: | Todd W. Garner | |
| Title: | Executive Vice President, Finance & | |
| Chief Financial Officer |
| NEWS RELEASE |
|---|
| CONTACT: |
| CONMED Corporation |
| Todd W. Garner |
| Chief Financial Officer |
| 727-214-2975 |
| ToddGarner@conmed.com |
CONMED Corporation Announces FirstQuarter 2025 Financial Results
Largo, Florida, April 30, 2025 –CONMED Corporation (NYSE: CNMD) today announced financial results for the first quarter ended March 31, 2025.
First Quarter 2025 Highlights
| · | Sales of $321.3 million increased 2.9% year-over-year<br>as reported and 3.8% in constant currency. |
|---|---|
| · | Domestic revenue increased 4.2% year-over-year. |
| --- | --- |
| · | International revenue increased 1.2% year-over-year<br>as reported and 3.4% in constant currency. |
| --- | --- |
| · | Diluted net earnings per share (GAAP) were $0.19, compared<br>to diluted net earnings per share (GAAP) of $0.63 in the first quarter of 2024. |
| --- | --- |
| · | Adjusted diluted net earnings per share^(1)^ were $0.95,<br>compared to adjusted diluted net earnings per share of $0.79 in the first quarter of 2024. |
| --- | --- |
“We had a good start to 2025, which positions us well to achieve our full-year guidance,” commented Patrick J. Beyer, CONMED’s President and Chief Executive Officer. “I am proud of our team’s dedication to strengthening our operations in order to better support our key growth platforms and drive long-term shareholder value.”
2025 Outlook
Based on current foreign currency exchange rates, the Company now expects revenue currency headwinds of approximately 50 to 70 basis points, compared to 100 to 120 basis points previously. As a result of the Company’s updated foreign currency expectations and its first quarter performance, full-year reported revenue is now expected to be between $1.350 billion and $1.378 billion, compared to the prior guidance range of between $1.344 billion and $1.372 billion.
Primarily as a result of these same updated foreign currency expectations and its first quarter performance, the Company now expects full-year adjusted diluted net earnings per share^(2)^ in the range of $4.45 to $4.60, compared to its prior range of $4.25 to $4.40.
This updated guidance does not include the effects of recent tariff announcements, which the Company estimates would result in a negative impact to EPS of approximately $0.14 in the second half of 2025.
Supplemental Financial Disclosures
^(1)^ A reconciliation of reported diluted net earnings per share to adjusted diluted net earnings per share, a non-GAAP financial measure, appears below.
^(2)^ Information reconciling forward-looking adjusted diluted net earnings per share to the comparable GAAP financial measures is unavailable to the company without unreasonable effort, as discussed below.
Conference Call
The Company’s management will host a conference call today at 4:30 p.m. ET to discuss its first quarter 2025 results.
To participate in the conference call via telephone, please click here to pre-register and obtain the dial-in number and passcode.
This conference call will also be webcast and can be accessed from the “Investors” section of CONMED's website at www.conmed.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.
Consolidated Condensed Statements of Income
(in thousands except per share amounts, unaudited)
| Three Months Ended | ||||
|---|---|---|---|---|
| March 31, | ||||
| 2025 | 2024 | |||
| Net sales | $ | 321,256 | $ | 312,273 |
| Cost of sales | 143,504 | 140,308 | ||
| Gross profit | 177,752 | 171,965 | ||
| % of sales | 55.3% | 55.1% | ||
| Selling & administrative expense | 148,847 | 123,358 | ||
| Research & development expense | 12,947 | 13,594 | ||
| Income from operations | 15,958 | 35,013 | ||
| % of sales | 5.0% | 11.2% | ||
| Interest expense | 8,286 | 9,594 | ||
| Income before income taxes | 7,672 | 25,419 | ||
| Provision for income taxes | 1,636 | 5,710 | ||
| Net income | $ | 6,036 | $ | 19,709 |
| Basic EPS | $ | 0.19 | $ | 0.64 |
| Diluted EPS | 0.19 | 0.63 | ||
| Basic shares | 30,973 | 30,780 | ||
| Diluted shares | 31,151 | 31,272 |
Sales Summary
(in millions, unaudited)
| Three<br> Months Ended March 31, | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| %<br> Change | ||||||||||||||||||
| Domestic | International | |||||||||||||||||
| 2025 | 2024 | As<br><br> Reported | Impact<br> <br><br> of<br><br> Foreign <br><br> Currency | Constant<br><br> Currency | As<br> <br><br> Reported | As<br><br> Reported | Impact<br> <br><br> of <br><br> Foreign <br><br> Currency | Constant<br> <br><br> Currency | ||||||||||
| Orthopedic Surgery | $ | 138.3 | $ | 134.9 | 2.5% | 1.4% | 3.9% | -2.1% | 5.6% | 2.3% | 7.9% | |||||||
| General Surgery | 183.0 | 177.4 | 3.2% | 0.6% | 3.8% | 6.9% | -5.2% | 1.9% | -3.3% | |||||||||
| $ | 321.3 | $ | 312.3 | 2.9% | 0.9% | 3.8% | 4.2% | 1.2% | 2.2% | 3.4% | ||||||||
| Single-use Products | $ | 276.3 | $ | 264.7 | 4.4% | 1.0% | 5.4% | 6.2% | 1.9% | 2.3% | 4.2% | |||||||
| Capital Products | 45.0 | 47.6 | -5.6% | 0.9% | -4.7% | -9.5% | -2.0% | 1.7% | -0.3% | |||||||||
| $ | 321.3 | $ | 312.3 | 2.9% | 0.9% | 3.8% | 4.2% | 1.2% | 2.2% | 3.4% | ||||||||
| Domestic | $ | 183.8 | $ | 176.4 | 4.2% | 0.0% | 4.2% | |||||||||||
| International | 137.5 | 135.9 | 1.2% | 2.2% | 3.4% | |||||||||||||
| $ | 321.3 | $ | 312.3 | 2.9% | 0.9% | 3.8% |
Reconciliation of Reported Net Income to AdjustedNet Income
(in thousands, except per share amounts, unaudited)
| Three Months<br> Ended March 31, 2025 | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Profit | Selling &<br> <br><br> Administrative <br><br> Expense | Operating<br><br> Income | Interest <br><br> Expense | Tax<br> Expense | Effective Tax<br> <br><br> Rate | Net Income | Diluted EPS | ||||||||||||||
| As reported | $ | 177,752 | $ | 148,847 | $ | 15,958 | $ | 8,286 | $ | 1,636 | 21.3% | $ | 6,036 | $ | 0.19 | ||||||
| % of sales | 55.3% | 46.3% | 5.0% | ||||||||||||||||||
| Executive transition costs^(1)^ | — | (12,165 | ) | 12,165 | — | 2,812 | 9,353 | ||||||||||||||
| Contingent consideration fair value adjustments^(2)^ | — | (3,962 | ) | 3,962 | — | 916 | 3,046 | ||||||||||||||
| Operational consulting fees^(3)^ | 3,410 | (490 | ) | 3,900 | — | 901 | 2,999 | ||||||||||||||
| Legal matters^(4)^ | — | (1,037 | ) | 1,037 | — | 240 | 797 | ||||||||||||||
| Gain on sale of product line^(5)^ | — | 354 | (354 | ) | — | (82 | ) | (272 | ) | ||||||||||||
| $ | 181,162 | $ | 131,547 | $ | 36,668 | $ | 8,286 | $ | 6,423 | $ | 21,959 | ||||||||||
| Adjusted gross profit % | 56.4% | ||||||||||||||||||||
| Amortization^(6)^ | $ | 1,500 | (7,172 | ) | 8,672 | (1,443 | ) | 2,455 | 7,660 | ||||||||||||
| As adjusted | $ | 124,375 | $ | 45,340 | $ | 6,843 | $ | 8,878 | 23.1% | $ | 29,619 | $ | 0.95 | ||||||||
| % of sales | 38.7% | 14.1% | |||||||||||||||||||
| Three Months Ended March 31, 2024 | |||||||||||||||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Gross Profit | Selling & <br><br>Administrative <br><br>Expense | Operating<br><br> Income | Interest <br> Expense | Tax<br> Expense | Effective Tax <br><br>Rate | Net Income | Diluted EPS | ||||||||||||||
| As reported | $ | 171,965 | $ | 123,358 | $ | 35,013 | $ | 9,594 | $ | 5,710 | 22.5% | $ | 19,709 | $ | 0.63 | ||||||
| % of sales | 55.1% | 39.5% | 11.2% | ||||||||||||||||||
| Contingent consideration fair value adjustments^(2)^ | — | 6,545 | (6,545 | ) | — | (940 | ) | (5,605 | ) | ||||||||||||
| Legal matters^(4)^ | — | (1,337 | ) | 1,337 | — | 192 | 1,145 | ||||||||||||||
| Restructuring and related costs^(7)^ | 235 | (1,539 | ) | 1,774 | — | 255 | 1,519 | ||||||||||||||
| Asset impairment costs^(8)^ | 1,414 | — | 1,414 | — | 203 | 1,211 | |||||||||||||||
| Termination of distributor agreement^(9)^ | — | 970 | (970 | ) | — | (139 | ) | (831 | ) | ||||||||||||
| $ | 173,614 | $ | 127,997 | $ | 32,023 | $ | 9,594 | $ | 5,281 | $ | 17,148 | ||||||||||
| Adjusted gross profit % | 55.6% | ||||||||||||||||||||
| Amortization^(6)^ | $ | 1,500 | (7,152 | ) | 8,652 | (1,407 | ) | 2,444 | 7,615 | ||||||||||||
| As adjusted | $ | 120,845 | $ | 40,675 | $ | 8,187 | $ | 7,725 | 23.8% | $ | 24,763 | $ | 0.79 | ||||||||
| % of sales | 38.7% | 13.0% |
(1) In 2025, the Company incurred cash and stock-based compensation costs related to advisory services provided by our former Chief Executive Officer.
(2) In 2025 and 2024, the Company recorded income/(expense) related to the fair value adjustments of contingent consideration.
(3) In 2025, the Company incurred costs related to the engagement of a consulting firm to evaluate and propose improvements to our manufacturing operations which are included in cost of sales. In addition, we incurred costs related to consultants which are included in selling & administrative expense.
(4) In 2025 and 2024, the Company incurred costs for third party services pertaining to potential issues with certain royalty payments to surgeons involved in design teams.
(5) In 2025, the Company recognized a gain on the sale of a product line.
(6) Includes amortization of intangible assets and deferred financing fees.
(7) In 2024, the Company incurred severance costs related to the elimination of certain positions.
(8) In 2024, the Company wrote off inventory, tooling and equipment related to the cancellation of a planned new product line.
(9) In 2024, the Company recorded an accrual adjustment related to the previous termination of a distributor agreement.
Reconciliation of Reported Net Income to EBITDA & Adjusted EBITDA
(in thousands, unaudited)
| Three Months Ended | ||||||
|---|---|---|---|---|---|---|
| March 31, | ||||||
| 2025 | 2024 | |||||
| Net income | $ | 6,036 | $ | 19,709 | ||
| Provision for income taxes | 1,636 | 5,710 | ||||
| Interest expense | 8,286 | 9,594 | ||||
| Depreciation | 4,235 | 4,046 | ||||
| Amortization | 14,018 | 13,992 | ||||
| EBITDA | $ | 34,211 | $ | 53,051 | ||
| Stock-based compensation | 6,381 | 6,240 | ||||
| Executive transition costs | 12,165 | — | ||||
| Contingent consideration fair value adjustments | 3,962 | (6,545 | ) | |||
| Operational consulting fees | 3,900 | — | ||||
| Legal matters | 1,037 | 1,337 | ||||
| Gain on sale of product line | (354 | ) | — | |||
| Restructuring and related costs | — | 1,774 | ||||
| Asset impairment costs | — | 1,414 | ||||
| Termination of distributor agreement | — | (970 | ) | |||
| Adjusted EBITDA | $ | 61,302 | $ | 56,301 | ||
| EBITDA Margin | ||||||
| EBITDA | 10.6% | 17.0% | ||||
| Adjusted EBITDA | 19.1% | 18.0% |
About CONMED Corporation
CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company’s products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. For more information, visit www.conmed.com.
Forward-Looking Statements
This press release and associated conference call may contain forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties, which could cause actual results, performance, or trends to differ materially from those expressed in the forward-looking statements herein or in previous disclosures. For example, in addition to general industry and economic conditions, factors that could cause actual results to differ materially from those in the forward-looking statements may include, but are not limited to the risk factors discussed in the Company's Annual Report on Form 10-K for the full year ended December 31, 2024 and other risks and uncertainties, which may be detailed from time to time in reports filed by CONMED with the SEC. Any and all forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company’s performance on a going-forward basis. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management’s expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct.
Supplemental Information - Reconciliationof GAAP to Non-GAAP Financial Measures
The Company supplements the reporting of its financial information determined under generally accepted accounting principles in the United States (GAAP) with certain non-GAAP financial measures, including percentage sales growth in constant currency; adjusted gross profit; cost of sales excluding specified items; adjusted selling and administrative expenses; adjusted operating income; adjusted interest expense; adjusted income tax expense; adjusted effective income tax rate; adjusted net income and adjusted diluted net earnings per share (EPS). The Company believes that these non-GAAP measures provide meaningful information to assist investors and shareholders in understanding its financial results and assessing its prospects for future performance. Management believes percentage sales growth in constant currency and the other adjusted measures described above are important indicators of its operations because they exclude items that may not be indicative of, or are unrelated to, its core operating results and provide a baseline for analyzing trends in the Company’s underlying business. Further, the presentation of EBITDA is a non-GAAP measurement that management considers useful for measuring aspects of the Company’s cash flow. Management uses these non-GAAP financial measures for reviewing the operating results and analyzing potential future business trends in connection with its budget process and bases certain management incentive compensation on these non-GAAP financial measures.
Net sales on a constant currency basis is a non-GAAP measure. The Company analyzes net sales on a constant currency basis to better measure the comparability of results between periods. To measure percentage sales growth in constant currency, the Company removes the impact of changes in foreign currency exchange rates that affect the comparability and trend of net sales. To measure earnings performance on a consistent and comparable basis, the Company excludes certain items that affect the comparability of operating results and the trend of earnings. These adjustments are irregular in timing, may not be indicative of past and future performance and are therefore excluded to allow investors to better understand underlying operating trends.
Because non-GAAP financial measures are not standardized, it may not be possible to compare these financial measures with other companies' non-GAAP financial measures having the same or similar names. These adjusted financial measures should not be considered in isolation or as a substitute for reported sales growth, gross profit, cost of sales, selling and administrative expenses, operating income, interest expense, income tax expense, effective income tax rate, net income and diluted net earnings per share, the most directly comparable GAAP financial measures. These non-GAAP financial measures are an additional way of viewing aspects of the Company’s operations that, when viewed with GAAP results and the reconciliations to corresponding GAAP financial measures above, provide a more complete understanding of the business. The Company strongly encourages investors and shareholders to review its financial statements and publicly filed reports in their entirety and not to rely on any single financial measure.
We are unable to present a quantitative reconciliation of our expected diluted net earnings per share to expected adjusted diluted net earnings per share as we are unable to predict with reasonable certainty and without unreasonable effort the impact and timing of acquisition, integration and other charges. The financial impact of these items is uncertain and is dependent on various factors, including timing, and could be material to our consolidated condensed statements of income.